**FOI Ref: 6480**

**Category(ies): Clinical - Service Activity**

**Subject: Radium- 223 Molecular Radiotherapy Use**

**Date Received: 06/07/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| **Question 1**  Please complete the table below:   |  |  | | --- | --- | | Radium-223 dichloride service |  | | Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n) | No - Patients are diagnosed at The Rotherham NHS Foundation Trust but are referred for Treatment to a Cancer Centre such as Sheffield Teaching Hospitals (STH).  Please redirect your request to Sheffield Teaching Hospitals, the email address for STH is [foi@sth.nhs.uk](mailto:foi@sth.nhs.uk) | | If yes, please list the indications for which it is used in your trust? |  | | |
| **Question 2**  Please detail the number of patients that are treated with radium-223 dichloride in your trust:   |  |  | | --- | --- | | Patient numbers |  | | Number of prostate cancer patients completing treatment with radium-223 dichloride per year |  | | Number of prostate cancer patients initiating radium-223 dichloride treatment per year |  | | What is the average number of cycles administered per patient in your service? |  | | What is the waiting time before patients can receive radium-223 dichloride? |  | | How many patients are initiated with cabazitaxel per year in your trust? |  | | |
| **Question 3**  In what department is molecular radiotherapy provided in your trust?   |  |  |  | | --- | --- | --- | | Administration | Radium-223 dichloride | 177Lutetium based radioligand therapy for neuroendocrine tumours | | Nuclear Medicine |  |  | | Medical Physics |  |  | | Radiotherapy |  |  | | Oncology |  |  | | Urology |  |  | | Other |  |  | | N/A |  |  | | |
| **Question 4**  What codes are associated with molecular radiotherapy administration in your trust?   |  |  |  | | --- | --- | --- | | NHS codes | HRG | OPCS code | | Radium-223 dichloride |  |  | | |
| **Question 5**  Please complete the table below:   |  |  |  | | --- | --- | --- | | Who performs the administration of the treatment? | Radium-223 dichloride | 177Lutetium based radioligand therapy for neuroendocrine tumours | | CNS |  |  | | Technician |  |  | | NM nurse |  |  | | NM physicist |  |  | | NM Consultant |  |  | | Oncologist |  |  | | Other *(please state)* |  |  | | |
| **Question 6**  Who holds the ARSAC licence in your trust?   |  |  |  |  | | --- | --- | --- | --- | | Administration | (y/n) | Radium-223 dichloride | 177Lutetium based radioligand therapy for neuroendocrine tumours | | Nuclear Medicine consultant |  |  |  | | Clinical Oncologist |  |  |  | | Radiologist |  |  |  | | Other *(please state speciality)* |  |  |  | | |
| **Question 7**  Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?   |  |  |  | | --- | --- | --- | | Radiation safety (y/n) | Conducted in-house  *(If so, please provide the number of full-time equivalents providing these services in your centre)* | Outsourced | | Radioactive Waste Adviser (RWA) |  |  | | Radiation Protection Adviser (RPA) |  |  | | Medical Physics Expert  (MPE) |  |  | | |
| **Question 8**  Please complete the table below:   |  |  |  |  | | --- | --- | --- | --- | | Dosimetry | (y/n) | If yes, what is the schedule after each administration? | If yes, is this analysed in-house or outsourced? | | Is dosimetry performed for radium-223 dichloride prostate cancer patients? |  |  |  | | |